Nitric Oxide Signaling in Heart Failure With Preserved Ejection Fraction

Lucas Cruz, MD; John J. Ryan, MD

JACC: Basic to Translational Science (Jun 2017)

Nitric Oxide Signaling in Heart Failure With Preserved Ejection Fraction

Lucas Cruz, MD,
John J. Ryan, MD

Affiliations

Lucas Cruz, MD: Department of Medicine, University of Connecticut, Hartford, Connecticut
John J. Ryan, MD: Division of Cardiovascular Medicine, Department of Medicine, University of Utah, Salt Lake City, Utah; Address for correspondence: Dr. John J. Ryan, Division of Cardiovascular Medicine, University of Utah Health Science Center, 30 North 1900 East, Room 4A100, Salt Lake City, Utah 84132.

Journal volume & issue: Vol. 2, no. 3
pp. 341 – 343

Abstract

Read online

Summary: There has been considerable focus on the potential role of nitric oxide (NO) and phosphodiesterase (PDE)-5 inhibition in treating heart failure with preserved ejection fraction (HFpEF). However, the results from studies have been conflicting. In a preclinical study, pre-treatment of diabetic rats with a PDE-5 inhibitor, vardenafil, resulted in a significant decrease in left ventricle stiffness. However, the results from clinical trials have been neutral. In this perspective piece, the authors discuss whether or not it is time to move on from targeting NO and PDE5 for the treatment of HFpEF. Key Words: nitrates, nitrites, phosphodiesterase, pulmonary arterial hypertension, sildenafil

Published in JACC: Basic to Translational Science

ISSN: 2452-302X (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the circulatory (Cardiovascular) system
Website: https://www.journals.elsevier.com/jacc-basic-to-translational-science/

About the journal